At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 8 enrolled
Drug / intervention
Immunolin®dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CCRC: A Pilot Project of the Treatment of HIV Enteropathy With ImmunoLin® Supplements
In Brief
A Early Phase 1 clinical trial evaluating Immunolin® for HIV. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The purpose of the study is to see if ImmunoLin® will reduce the frequency of bowel movements and gastrointestinal (GI) symptoms in HIV volunteers with persistent GI symptoms. The study will also examine the effect of ImmunoLin® on the bacteria in the gut and the immune system in gut tissue as well as in the blood.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States
CollaboratorsProliant Health & Biologicals
Timeline
Early Ph 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionAug 2012
TodayJul 2026
First PostedMar 14, 2011
Enrollment StartMar 1, 2011
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.3 years ago
Interventions
Immunolin®dietary
Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks